Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
Significant Development Supports Long-Term Global Commercial Strategy of the LIBERTY® SystemHINGHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, announced that it has been granted a critical patent in China by the China National Intellectual Property Administration (CNIPA), a key step in the Company’s global IP expansion strategy. The patent, which covers the robotic manipulation of a surgical tool handle, fu ...